Highest-materiality recent filing
Exicure derivative settlement preliminarily approved; includes governance reforms and $675k fee
Court preliminarily approved settlement on March 19, 2026; final hearing set for June 2, 2026.
Exicure FY2025 net loss $4.9M; cash $3.7M; warns cash insufficient for 12 months
Cash and cash equivalents $3.7M as of Dec 31 2025, down from $12.5M a year ago.
Exicure appoints Jung Soo Kim as CEO and Gyuyeob Lee as interim CFO
CEO Andy Yoo and CFO Seung Ik Baik resigned effective Feb 9, 2026.
Exicure CEO Andy Yoo, CFO Seung Ik Baik resign; three new directors appointed
Andy Yoo resigned as CEO/President and Seung Ik Baik as CFO/Secretary, effective Feb 9, 2026; no successors named.
Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics
Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.
Exicure Q3 net loss widens to $2.4M; cash burn and going concern warning
Cash and cash equivalents fell to $4.4M at Sep 30, 2025 from $12.5M at Dec 31, 2024.
Exicure appoints two new directors; four directors resign effective Sept 8, 2025
Appointed Sangjn Yeo and Aejin Hwang to the Board as Class II directors; Yeo appointed Chairman of audit committee.
Exicure reports Q2 net loss of $2.6M; warns going concern, needs financing
Cash and equivalents fell to $7.9M at June 30, 2025, from $12.5M at Dec 31, 2024.
Exicure reports Q1 net income of $3.0M on lease gain; warns cash insufficient for operations
Cash and equivalents $10.4M (Dec 2024: $12.5M); net income $3.0M vs loss $0.8M YoY.
Exicure receives Nasdaq delinquency notice for late Q1 2025 Form 10-Q filing
Received Nasdaq delinquency notice on May 21, 2025 for failure to timely file Form 10-Q for quarter ended March 31, 2025.
Exicure reports FY2024 net loss of $9.7M, cash $12.5M, going concern warning
Cash and cash equivalents $12.5M as of Dec 31, 2024, up from $0.8M year-end 2023; management warns liquidity may not last 12 months.
Exicure raises ~$2M in stock sale to two investors; records $6M lease-termination gain
Raised ~$2M via sale of 290,908 shares at $5.50 each to Shin Chang Partners and RMS0718 Co., Ltd.
Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement
Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.
Exicure buys GPCR USA for ~$1.62M; milestone & royalty deal with GPCR Therapeutics
Acquired all outstanding shares of GPCR Therapeutics USA from GPCR Therapeutics for ~$0.27/share (total ~$1.62M).
Exicure receives $8.7M from HiTron, appoints audit committee members
Received $8.7M on Dec 24, 2024 from closing of Common Stock Purchase Agreement with HiTron Systems Inc.
Exicure shareholders approve $8.7M HiTron investment; CEO and board changes; Nasdaq plan presented
Shareholders approved $8.7M second investment from HiTron; total HiTron investment $10M at $3/share.
On Dec 20, 2024, Nasdaq confirmed Exicure meets all requirements for continued listing as of Dec 17, 2024.
Exicure shareholders approve $8.7M HiTron investment; change of control, new CEO and board
Shareholders approved 2.9M shares to HiTron at $3/share for $8.7M second investment, totaling $10M; HiTron holds >50%.
Exicure raises $12M via stock sales to regain Nasdaq equity compliance; pro forma equity ~$4.3M
Sold 433K shares to HiTron Systems at $3/share for $1.3M net proceeds on Nov 21, 2024.
Exicure to issue 433,332 shares at $4.61 for $2M gross proceeds to SangSangIn
Common Stock Purchase Agreement with SangSangIn Investment & Securities Co., Ltd.
Exicure appoints new board members and CRO; receives $1.3M from HiTron deal closing
Andy Yoo appointed as Class I director and Chief Restructuring Officer; Seung Ik Baik as Class III director effective Nov 21, 2024.
Exicure gets Nasdaq extension to Dec 17; delisting risk persists
Nasdaq Hearings Panel granted extension to December 17, 2024, for listing compliance.
Exicure announces $10M equity financing from HiTron, Q3 net loss $1.1M, cash $0.3M
Initial sale of 433,333 shares at $3.00/share to HiTron for $1.3M; closing expected within 10 days.
Exicure sells core SNA technology to Flashpoint for $1.5M; appoints new director
Sold spherical nucleic acid technology, R&D programs, and clinical assets to Flashpoint Therapeutics for $1.5 million gross proceeds.
Exicure converts $1M debt to equity at $3/share; regains Nasdaq compliance
Converted $700K promissory note from DGP Co., Ltd. into 237,233 shares at $3.00/share.
Exicure special meeting adjourned; quorum not reached at 49.4% votes
Special meeting on Aug 15 adjourned due to lack of quorum; only 49.4% of outstanding shares voted.
Exicure Q2 2024 net loss $0.6M; cash only $0.5M, warns of insufficient funding and going concern
Cash and cash equivalents $0.5M at June 30, 2024, down from $0.8M at Dec 31, 2023.
Exicure gets Nasdaq continued listing with Sept. 16 compliance deadline
Nasdaq Hearings Panel determined to continue Exicure's listing subject to evidencing compliance by September 16, 2024.
Exicure receives Nasdaq delisting notice for minimum equity failure
Received Nasdaq delinquency notice on June 20, 2024 for non-compliance with minimum $2.5M stockholders' equity requirement.
Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern
Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.
Cash and cash equivalents fell to $0.8M at Dec 2023 and further to ~$0.2M by May 31, 2024.
Nasdaq notified Exicure on May 21 of delisting; trading suspension effective May 30 unless appeal by May 28.
Exicure cash drops to $0.2M; warns going concern, needs funding imminently
Cash and equivalents fell from $8.6M (Dec 31, 2022) to $0.9M (Sep 30, 2023); further to ~$0.2M by Apr 30, 2024.
Exicure receives Nasdaq delinquency notice for late 10-K; must comply by May 20, 2024
On April 17, 2024, Nasdaq notified Exicure of non-compliance for failing to file its 2023 Form 10-K (Rule 5250(c)(1)).
In conjunction with the execution of this consulting agreement, Mr. Kang resigned from the Board for personal reasons, effective as of March 3, 2025.
On February 28, 2025, Jiyoung Hwang resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) for personal reasons, effective immediately as of such date.
the Company announced the appointment of Chang Keun Choi and Minwoo Kang to the Company's Board of Directors (the 'Board'), effective December 19, 2024.
the Company announced the appointment of Chang Keun Choi and Minwoo Kang to the Company's Board of Directors (the 'Board'), effective December 19, 2024.
effective January 1, 2005, Mr. Choi and Mr. Kang have been appointed to the Audit Committee of the Board, with Mr. Kang serving as the Chair of the Audit Committee.
on November 21, 2024, the Board of Directors (the "Board’) of the Company appointed Andy Yoo and Seung Ik Baik to the Board.
on November 21, 2024, the Board of Directors (the "Board’) of the Company appointed Andy Yoo and Seung Ik Baik to the Board.
On November 21, 2024, Eui Yull Hwang resigned from the Board for personal reasons, effective immediately as of such date.
On November 21, 2024, Hojoon Lee resigned from the Board for personal reasons, effective immediately as of such date.
The Board also appointed Mr. Yoo as the Chief Restructuring Officer of the Company and entered into an employment agreement with Mr. Yoo effective November 21, 2024.
On September 26, 2024, the Board increased the size of the Board from six directors to seven directors and appointed Eui Yull Hwang as an independent director to fill the vacancy.
Max materiality 1.00 · Median 0.70 · Most common event other_material